> BioMed X and Boehringer Ingelheim added another strand to their multiyear collaboration. The new project will support research into targets for early interventions into psychiatric diseases. Release
> Nanobiotix unveiled plans to list its stock in the U.S. Statement
> Boehringer Ingelheim teamed up with Bioharmony Therapeutics to develop bacteriophage lysins to treat multidrug resistant infections. Release
> Sanofi secured access to Biomunex Pharmaceuticals’ technology for optimizing bispecific and multispecific antibodies. Statement (PDF)
> Shares in Hansa Medical slipped after it revealed the FDA has asked for more information on its kidney disease drug imlifidase. Hansa plans to file for approval in Europe this quarter but is yet to commit to a timeline in the U.S. Release
> EFPIA reiterated its request to temporarily exempt clinical trial materials from customs checks in the event of a no-deal Brexit after British politicians voted against the withdrawal agreement. Statement